Clinical Trial Update: Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 safety and dose-determining study of BT062 in relapsed or refractory multiple myeloma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BT062

Snippet

Sponsor: Biotest Pharmaceuticals Corporation | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED